Depression, antidepressants and heart disease

Drug and Therapeutics Bulletin

Volumn 46, Issue 4, 2008, Pages 29-32

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; DILTIAZEM; DOSULEPIN; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; LOFEPRAMINE; METOPROLOL; MIANSERIN; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; PROPRANOLOL; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE; VERAPAMIL;

ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEPRESSION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE INCREASE; DRUG METABOLISM; DRUG OVERDOSE; DRUG WITHDRAWAL; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART CONDUCTION; HEART DEATH; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART PALPITATION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR DEPRESSION; ORTHOSTATIC HYPOTENSION; PROGNOSIS; QT PROLONGATION; SIDE EFFECT; STROKE; TACHYCARDIA; THROMBOCYTE FUNCTION; TORSADE DES POINTES; UNSTABLE ANGINA PECTORIS;

ANTIDEPRESSIVE AGENTS; CARDIOTONIC AGENTS; DEPRESSIVE DISORDER; DRUG INTERACTIONS; HEART DISEASES; HUMANS; PROGNOSIS;

EID: 44649143777     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2008.03.0009     Document Type: Article

References (30)

1. Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998; 155: 4-11.
2. Nicholson A et al. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J 2006; 27: 2763-74.
3. van Melle JP et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 2004; 66: 814-22.
4. Carney RM et al. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res 2002; 53: 897-902.
5. Coupland N et al. Antidepressant drugs and the cardiovascular system: a comparison of tricyclics and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. J Psychopharmacol 1997; 11: 83-92.
6. Roose SP, Glassman AH. Antidepressant choice in the patient with cardiac disease: lessons from the cardiac arrhythmia suppression trial (CAST) studies. J Clin Psychiatry 1994; 55 (suppl A): 83-7.
7. Reid F, Henry JA. Lofepramine overdosage. Pharmacopsychiat 1990; 23: 23-7.
8. Buckley NA et al. Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet 1994, 343: 159-62.
9. Prothiaden Tablets 75mg. Summary of product characteristics, UK. Abbott Laboratories Limited, July 2007.
10. Khawaja IS, Feinstein RE. Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants. Heart Dis 2003; 5: 153-60.
11. Serebruany VL et al. Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. Am J Cardiol 2001; 87: 1398-400.
12. Swenson JR et al. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Can J Psychiatry 2006; 51: 923-9.
13. Efexor. Summary of product characteristics, UK. John Wyeth and brother Ltd, May 2006.
14. Mines D et al. Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol Drug Saf 2005; 14: 367-72.
15. Medical and Healthcare products Regulatory Agency, 2006. Venlafaxine (Efexor): summary of basis for regulatory position [online]. Available: http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON2023843 [Accessed 27 March 2008).
16. Cymbalta 30mg hard gastro-resistant capsules, Cymbalta 60mg hard gastro-resistant capsules. Summary of product characteristics, EU. Eli Lilly Nederland BV, August 2007.
17. Haine SE et al. Mianserin and ventricular tachycardia: case report and review of the literature. Cardiol 2006; 106: 195-8.
18. Mirtazapine 15mg Tablets x 28, Summary of product characteristics, UK. Genus Pharmaceutical Limited, May 2005.
19. Manerix. Summary of product characteristics, UK. Roche Products Limited, February 2008.
20. Edronax 4mg Tablets. Summary of product characteristics, UK. Pharmacia Limited, April 2007.
21. Molipaxin 50mg and 100mg capsules. Summary of product characteristics, UK. Sanofi-Aventis, November 2007.
22. Nelson JC et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am J Psychiatry 1999; 156: 1024-8.
23. Rooso SP et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998; 279: 287-91.
24. Lesperance F et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007; 297: 367-9.
25. Glassman AH et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701-9.
26. Strik JJMH et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo controlled trial. Psychosomatic Med 2000: 62: 783-9.
27. Honig A et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Med 2007;69:606-13.
28. Berkman LF et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease patients (ENRICHD) randomized trial. JAMA 2003;289:3106-16.
29. Baxter K (Ed). Stockley's Drug Interactions. Eighth edition. London, Chicago: Pharmaceutical Press, 2008.
30. National Institute for Health and Clinical, Excellence, 2007. Depression: management of depression in primary and secondary care [online]. Available: http:/www.nice.org.uk/nicemedia/pdf/ CG23fullguideline.pdf [Accessed 27 March 2008].